BMS-986278
- Generic Name
- BMS-986278
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31N5O5
- CAS Number
- 2170126-74-4
- Unique Ingredient Identifier
- 4UN9AOU6G8
Novel Pipeline Therapies Show Promise for Pulmonary Sarcoidosis Treatment
DelveInsight's latest pipeline report reveals over 10 companies actively developing treatments for pulmonary sarcoidosis. Key players including Novartis and aTyr Pharma are advancing innovative therapies, with CMK389 and ATYR1923 showing particular promise in clinical development.
Boehringer Ingelheim's Nerandomilast Shows Promise in Phase III Trials for Pulmonary Fibrosis
• Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase III FIBRONEER-ILD trial, improving lung function in patients with progressive pulmonary fibrosis.
• The company plans to submit a New Drug Application (NDA) to the FDA and other health authorities for nerandomilast in progressive pulmonary fibrosis.
• Nerandomilast, an oral PDE4B inhibitor, has also shown positive results in a separate Phase III trial for idiopathic pulmonary fibrosis (IPF), with an NDA already submitted.
• The FIBRONEER-ILD trial included 1,178 patients across 40 countries, evaluating two doses of nerandomilast against placebo over 52 weeks.
IPF Drug Development Heats Up with Novel Targets and Clinical Advances
• Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms.
• Boehringer Ingelheim plans to submit an NDA for nerandomilast after a successful Phase 3 trial showing improved lung function in IPF patients.
• Endeavor BioMedicines' ENV-101 and Insilico Medicine's ISM001-055 demonstrate promising results in improving lung function and reducing fibrosis in Phase 2 trials.
• Bristol Myers Squibb's BMS-986278, an LPA1 antagonist, received FDA Breakthrough Therapy Designation after reducing the rate of FVC decline by 69% in a Phase 2 study.
Nerandomilast Shows Promise in Phase 3 Trial for Idiopathic Pulmonary Fibrosis
• Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase 3 FIBRONEER-IPF trial, demonstrating improved lung function in IPF patients.
• The trial is the first in a decade to meet its primary endpoint, offering hope for a new treatment option for this progressive disease.
• Nerandomilast, a phosphodiesterase 4B inhibitor, aims to reduce inflammation and fibrosis in the lungs, addressing a high unmet need.
• Full data will be presented in the first half of 2025, with plans for regulatory submissions to the FDA and other agencies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath